Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group (Helsinn), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, and Xediton Pharmaceuticals Inc. (Xediton), a Canadian based specialty pharmaceutical company with a strong presence in products in Oncology, announced today the signing of an exclusive license and distribution agreement in Canada for TRUSELTIQ™ (infigratinib), which was recently approved under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.